Skip to main content
. Author manuscript; available in PMC: 2021 Jun 15.
Published in final edited form as: Vaccine. 2020 May 22;38(29):4616–4624. doi: 10.1016/j.vaccine.2020.04.079

Table 3.

Base case results for the cost-effectiveness of administering a '0' MCV dose compared to initiating the measles vaccination schedule at 8 months in China

Age of Vaccination Costs per infant (US$) QALYs per infant ICER (US$)┼
Adding a measles dose for infants
 4 months $ 4.50 30.8435 $ 232.70
 5 months $ 4.50 30.8431 $ 238.39
 6 months $ 4.51 30.8423 $ 251.22
 7 months $ 4.57 30.8400 $ 302.39
Comparator (no additional dose)
 8 months $ 0.70 30.8272 -
┼

ICER = Incremental cost-effectiveness ratio compares the net costs and QALYs gained per infant when a ‘0 dose’ is added to the current measles vaccination schedule in China to the net costs and QALYs gained per infant under the current strategy alone, where the ICER = (cost at X months – cost at 8 months)/(QALYs at X months – QALYs at 8 months) for each “age of vaccination” scenario for adding a measles dose at X months.